COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #205 of 260
12/4 Late treatment study
Modrák et al., medRxiv, doi:10.1101/2020.12.03.20239863 (Preprint)
Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis
Source   PDF   Share   Tweet
Retrospective 213 hospitalized patients in Czech Republic showing lower mortality with HCQ. Subject to confounding by indication.

Modrák et al., 12/4/2020, retrospective, Czech Republic, Europe, preprint, 26 authors.
risk of death, 59.0% lower, RR 0.41, p = 0.04, treatment 108, control 105, Cox (single).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 260 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit